Literature DB >> 1827288

Diploid predominance and prognostic significance of S-phase cells in malignant mesothelioma.

S Pyrhönen1, A Laasonen, L Tammilehto, J Rautonen, S Anttila, K Mattson, L R Holsti.   

Abstract

70 histologically verified, malignant mesotheliomas were analysed by flow cytometry for DNA content and S-phase fraction (SPF) of tumour cells. 60% (42/70) were DNA diploid. 18 of the 28 aneuploid tumours were near-diploid with DNA indices of 1.3 or less. SPF could be calculated in 51 cases. SPF was significantly higher in aneuploid (median 16.0%) than in diploid tumours (median 5.6%). DNA ploidy was not a prognostic determinant; survival was the same for both aneuploid and diploid tumours. SPF, however, was significantly correlated (P = 0.039) with prognosis. Patients who had tumours with a low SPF survived almost twice as long as those with a high SPF. Thus malignant mesothelioma has a peculiar DNA ploidy pattern compared with many other solid tumours, with a predominance of diploid or near-diploid type cells. As in many other tumours, SPF may be used as a clinically relevant prognostic indicator.

Entities:  

Mesh:

Year:  1991        PMID: 1827288     DOI: 10.1016/0277-5379(91)90487-x

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  3 in total

1.  Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma.

Authors:  A M Björkqvist; L Tammilehto; S Anttila; K Mattson; S Knuutila
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

2.  Tumour growth rate and DNA flow cytometry parameters as prognostic factors in metastatic melanoma.

Authors:  T Muhonen; S Pyrhönen; A Laasonen; V M Wasenius; S Asko-Seljavaara; K Franssila; L Kangas
Journal:  Br J Cancer       Date:  1992-09       Impact factor: 7.640

3.  DNA aneuploidy and low S-phase fraction as favourable prognostic signs in metastatic melanoma.

Authors:  T Muhonen; S Pyrhönen; A Laasonen; S Asko-Seljavaara; K Franssila
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.